These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34433362)

  • 1. Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland.
    Tschacher A; Cadus C; Schildge S; Diedrich JP; Chhajed PN; Leuppi-Taegtmeyer AB; Leuppi JD
    Curr Med Res Opin; 2021 Nov; 37(11):2019-2033. PubMed ID: 34433362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler.
    Dhand R; Eicher J; Hänsel M; Jost I; Meisenheimer M; Wachtel H
    Int J Chron Obstruct Pulmon Dis; 2019; 14():509-523. PubMed ID: 30880941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced Environmental Impact of the Reusable Respimat
    Hänsel M; Bambach T; Wachtel H
    Adv Ther; 2019 Sep; 36(9):2487-2492. PubMed ID: 31317391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of inhalation technique assessment service for patients with Respimat® inhaler.
    Rossi V; Salimäki J; Sandler C; Airaksinen M; Kauppi P
    Pulm Pharmacol Ther; 2021 Dec; 71():102077. PubMed ID: 34534672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD.
    Miravitlles M; Montero-Caballero J; Richard F; Santos S; Garcia-Rivero JL; Ortega F; Ribera X
    Int J Chron Obstruct Pulmon Dis; 2016; 11():407-15. PubMed ID: 27013871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Patient Experiences with Respimat
    Taube C; Bayer V; Zehendner CM; Valipour A
    Pulm Ther; 2020 Dec; 6(2):371-380. PubMed ID: 32857327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey.
    Price D; Keininger DL; Viswanad B; Gasser M; Walda S; Gutzwiller FS
    Int J Chron Obstruct Pulmon Dis; 2018; 13():695-702. PubMed ID: 29520137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.
    Hodder R; Price D
    Int J Chron Obstruct Pulmon Dis; 2009; 4():381-90. PubMed ID: 19888356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient perceptions of the re-usable Respimatt
    Dreher M; Price D; Gardev A; Peeters P; Arora S; van der Sar-van der Brugge S; Dekhuijzen R; Usmani OS
    Chron Respir Dis; 2021; 18():1479973120986228. PubMed ID: 33522304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction.
    Schürmann W; Schmidtmann S; Moroni P; Massey D; Qidan M
    Treat Respir Med; 2005; 4(1):53-61. PubMed ID: 15725050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technical Evaluation of Soft Mist Inhaler Use in Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study.
    Zhang W; Xu L; Gao S; Ding N; Shu P; Wang Z; Li Y
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1471-1479. PubMed ID: 32606655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD.
    Kilfeather SA; Ponitz HH; Beck E; Schmidt P; Lee A; Bowen I; Hesse Ch
    Respir Med; 2004 May; 98(5):387-97. PubMed ID: 15139567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
    Brand P; Hederer B; Austen G; Dewberry H; Meyer T
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):763-70. PubMed ID: 19281091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler.
    Hodder R; Pavia D; Dewberry H; Alexander K; Iacono P; Ponitz H; Beck E
    Respir Med; 2005 Sep; 99(9):1087-95. PubMed ID: 15893465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
    Kässner F; Hodder R; Bateman ED
    Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the preference, satisfaction and correct use of Breezhaler
    Oliveira MVC; Pizzichini E; da Costa CH; Fritscher CC; Vianna EO; Teixeira PJZ; Stirbulov R; Rabahi MF; Pinho NC
    Respir Med; 2018 Nov; 144():61-67. PubMed ID: 30366585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Inhaler Satisfaction and Determinants of High Satisfaction Among Korean COPD Patients.
    Jang JG; Lee KH; Chung JH; Shin KC; Choi EY; Jin HJ; Ahn JH
    J Korean Med Sci; 2022 Nov; 37(46):e327. PubMed ID: 36631025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium versus placebo for chronic obstructive pulmonary disease.
    Karner C; Chong J; Poole P
    Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler.
    Hodder R; Reese PR; Slaton T
    Int J Chron Obstruct Pulmon Dis; 2009; 4():225-32. PubMed ID: 19554196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.